Associations between vaspin rs2236242 gene polymorphism, walking time and the risk of metabolic syndrome

AbstractThe associations between serum vaspin levels and metabolic or coronary artery disease (CAD) and polycystic ovary syndrome (PCOS) is under the scope of current researchers. Therefore, this adipokine can be considered as a biomarker of metabolic syndrome (MetS). The aim of the study was to analyze the associations between the vaspin rs2236242 polymorphism and physical activity in relation to MetS and its components. The analysis involved the genetic material and clinical data of 108 individuals with MetS and 110 controls. Vaspin rs2236242 polymorphism was detected using the tetra-primer amplification-refractory mutation system polymerase chain reaction (T-ARMS PCR) method. The TA genotype of vaspin rs2236242 was associated with a greater risk of MetS and its components compared with the TT genotype. The analysis of interactions between genotype and walking time revealed that a walking time longer than 60 min./day significantly decreased the risk of MetS in the TA carriers (p = 0.007). The obtained results suggest that any unfavorable effect of the TA genotype of the vaspin rs2236242 polymorphism can be essentially reduced, or even reversed, in a case of individuals walking longer than 60 min. a day. The analysis of the interaction between vaspin rs2236242 polymorphism and walking showed that a walking time of longer than 1 hour a day significantly reduced the risk of MetS, elevated blood pressure and triglycerides concentration.

Download Full-text

FABP1 gene variant associated with risk of metabolic syndrome

Combinatorial Chemistry & High Throughput Screening ◽

10.2174/1386207324666210603114434 ◽

2021 ◽

Vol 24 ◽

Author(s):

Reza Zare-Feyzabadi ◽

Majid Mozaffari ◽

Majid Ghayour-Mobarhan ◽

Mohsen Valizadeh

Keyword(s):

Metabolic Syndrome ◽

International Diabetes Federation ◽

Amplification Refractory Mutation System ◽

Study Cohort ◽

Increased Risk ◽

Mutation System ◽

Polymerase Chain ◽

The Relationship ◽

Diabetes And Obesity

Background: Metabolic Syndrome (MetS) is defined by a clustering of metabolic abnormalities associated with an increased risk of cardiovascular disease and type 2 diabetes mellitus. There has been an increasing interest in the associations of genetic variants involved in diabetes and obesity in the FABP1 pathway. The relationship between the rs2241883 polymorphism of FABP1 and risk of MetS remains unclear. Objective: We aimed to examine the association between this genetic polymorphism and the presence of MetS and its constituent factors. Methods: A total of 942 participants were recruited as part of the Mashhad Stroke and Heart Atherosclerosis Disorders (MASHAD study) Cohort. Patients with MetS were identified using the International Diabetes Federation (IDF) criteria (n=406) and those without MetS (n=536) were also recruited. DNA was extracted from peripheral blood samples and used for genotyping of the FABP1 rs2241883T/C polymorphism using Tetra-Amplification Refractory Mutation System Polymerase Chain Reaction (Tetra-ARMS PCR). Genetic analysis was confirmed by gel electrophoresis and DNA sequencing. Results: Using both univariate and multivariate analyses after adjusting for age, sex and physical activity, carriers of C allele (CT/CC genotypes) in FABP1 variant were related to an increased risk of MetS, compared to non-carriers (OR: 1.38, 95%CI: 1.04,1.82, p=0.026). Conclusion: The present study shows that C allele in the FABP1 variant can be associated with an increased risk of MetS. The evaluation of these factors in a larger population may help further confirm these findings.

Download Full-text

Association of Functional Polymorphism in Protein Tyrosine Phosphatase Nonreceptor 22 (PTPN22) Gene with Vitiligo

Biomarker Insights ◽

10.1177/1177271920903038 ◽

2020 ◽

Vol 15 ◽

pp. 117727192090303

Author(s):

Ghaleb Bin Huraib ◽

Fahad Al Harthi ◽

Misbahul Arfin ◽

Abdulrahman Aljamal ◽

Abdulqader Saeed Alrawi ◽

...

Keyword(s):

Protein Tyrosine Phosphatase ◽

Tyrosine Phosphatase ◽

Amplification Refractory Mutation System ◽

Functional Polymorphism ◽

Ptpn22 Gene ◽

Protein Tyrosine ◽

Mutation System ◽

Pcr Method ◽

Polymerase Chain ◽

Saudi Arabians

The protein tyrosine phosphatase nonreceptor 22 (PTPN22) is associated with susceptibility to autoimmune diseases. The functional polymorphism in PTPN22 at 1857 is a strong risk factor for vitiligo susceptibility in Europeans; however, controversy exits in other populations. Present study was aimed to determine whether the PTPN22 C1857T polymorphism confers susceptibility to vitiligo in Saudi Arabians. Genomic DNA was extracted and amplified using tetra primer amplification-refractory mutation system polymerase chain reaction (ARMS-PCR) method. The frequencies of allele T and genotype CT of PTPN22 C1858T polymorphism were significantly higher, whereas those of allele C and genotype CC were lower in patients as compared with controls ( P < 0.0001). The genotype TT was absent in both the patients and controls. It is concluded that PTPN22 C1858T polymorphism is strongly associated with vitiligo susceptibility. However, additional studies are warranted using large number of samples from different ethnicities and geographical areas.

Download Full-text

Noninvasive prenatal screening test for compound heterozygous beta thalassemia using an amplification refractory mutation system real-time polymerase chain reaction technique

Hematology Reports ◽

10.4081/hr.2019.8124 ◽

2019 ◽

Vol 11 (3) ◽

Cited By ~ 1

Author(s):

Narutchala Suwannakhon ◽

Tanapat Pangeson ◽

Teerapat Seeratanachot ◽

Khwanruedee Mahingsa ◽

Arunee Pingyod ◽

...

Keyword(s):

Polymerase Chain Reaction ◽

Real Time ◽

Beta Thalassemia ◽

Amplification Refractory Mutation System ◽

Rt Pcr ◽

Chain Reaction ◽

Mutation System ◽

Pcr Method ◽

Polymerase Chain ◽

Thalassemia Mutation

We propose using a modified amplification refractory mutation system real-time polymerase chain reaction (ARMS RTPCR) technique to exclude the invasive prenatal diagnosis for a non-paternally inherited beta thalassemia mutation in couples atrisk for having a baby with CHBT. The ARMS RT-PCR method was performed for 36 at-risk couples by using isolated fetal cell-free DNA from maternal plasma. The modified ARMS RT-PCR primers targeted one of the following paternally inherited beta thalassemia mutation: -28 A→G, CD17 A→T, CD 26 G→A, IVS1-1 G→T and CD 41-42 -CTTT. The method could be successfully employed for NIPST starting with the 7th week of gestation. The results showed that 19 pregnant women were negative for PIBTM (53%). After an on-track and on-time of one year, including postnatal thalassemia blood tests, none of the babies showed symptoms or signs of beta thalassemia disease. We concluded that the modified ARMS RT-PCR method was an accurate, cost-effective and feasible method for use as a NIPST for at-risk couples with the potential of having a baby with CHBT.

Download Full-text

Abstract #781: Association Between the Polycystic Ovary Syndrome and the Metabolic Syndrome in Women in Puerto Rico

Endocrine Practice ◽

10.1016/s1530-891x(20)43640-7 ◽

2005 ◽

Vol 11 ◽

pp. 66

Author(s):

Marielsa Rabelo ◽

Margarita Ramírez

Keyword(s):

Metabolic Syndrome ◽

Puerto Rico ◽

Polycystic Ovary Syndrome ◽

Polycystic Ovary ◽

Ovary Syndrome ◽

The Metabolic Syndrome

Download Full-text

Value of lipid accumulation product for the assessment of metabolic syndrome in women with polycystic ovary syndrome

Endocrine Abstracts ◽

10.1530/endoabs.32.p588 ◽

2013 ◽

Author(s):

Antic Ivana Bozic ◽

Jelica Bjekic-Macut ◽

Dimitrios Panidis ◽

Danijela Vojnovic Milutinovic ◽

Biljana Kastratovic ◽

...

Keyword(s):

Metabolic Syndrome ◽

Polycystic Ovary Syndrome ◽

Lipid Accumulation ◽

Polycystic Ovary ◽

Lipid Accumulation Product ◽

Ovary Syndrome

Download Full-text

Prevalence of metabolic syndrome in obese women with polycystic ovary syndrome

Endocrine Abstracts ◽

10.1530/endoabs.35.p624 ◽

2014 ◽

Author(s):

Ivana Bozic Antic ◽

Djuro Macut ◽

Jelica Bjekic-Macut ◽

Danijela Vojnovic Milutinovic ◽

Milan Petakov ◽

...

Keyword(s):

Metabolic Syndrome ◽

Polycystic Ovary Syndrome ◽

Polycystic Ovary ◽

Obese Women ◽

Ovary Syndrome

Download Full-text

Metabolic Syndrome During Menopause

Current Vascular Pharmacology ◽

10.2174/1570161116666180904094149 ◽

2019 ◽

Vol 17 (6) ◽

pp. 595-603 ◽

Cited By ~ 4

Author(s):

Sezcan Mumusoglu ◽

Bulent Okan Yildiz

Keyword(s):

Insulin Resistance ◽

Metabolic Syndrome ◽

Central Obesity ◽

Polycystic Ovary ◽

Ovary Syndrome ◽

Natural Menopause ◽

The Metabolic Syndrome ◽

Increased Risk ◽

Aging Women

The metabolic syndrome (MetS) comprises individual components including central obesity, insulin resistance, dyslipidaemia and hypertension and it is associated with an increased risk of cardiovascular disease (CVD) and type 2 diabetes mellitus (T2DM). The menopause per se increases the incidence of MetS in aging women. The effect(s) of menopause on individual components of MetS include: i) increasing central obesity with changes in the fat tissue distribution, ii) potential increase in insulin resistance, iii) changes in serum lipid concentrations, which seem to be associated with increasing weight rather than menopause itself, and, iv) an association between menopause and hypertension, although available data are inconclusive. With regard to the consequences of MetS during menopause, there is no consistent data supporting a causal relationship between menopause and CVD. However, concomitant MetS during menopause appears to increase the risk of CVD. Furthermore, despite the data supporting the association between early menopause and increased risk of T2DM, the association between natural menopause itself and risk of T2DM is not evident. However, the presence and the severity of MetS appears to be associated with an increased risk of T2DM. Although the mechanism is not clear, surgical menopause is strongly linked with a higher incidence of MetS. Interestingly, women with polycystic ovary syndrome (PCOS) have an increased risk of MetS during their reproductive years; however, with menopausal transition, the risk of MetS becomes similar to that of non-PCOS women.

Download Full-text